ATAI Life Sciences AG

Our management team will participate in the H.C. Wainwright & Co., LLC Neuro Perspectives conference on Thursday June 27.   Co-CEOs Srinivas Rao and Florian Brand will engage in a fireside chat which will be available on-demand from 7:00 am ET via the following link. https://lnkd.in/ekjwjJc4   There will be a replay on the Investors section of our website under Events for 90 days.    #NeuroPerspectives #MentalHealth

Read our Co-Founder and Co-CEO’s HLTH Europe recap below 👇

📣 Exciting update on Beckley Psytech’s Phase 1/2a trial of ELE-101 (IV psilocin) for major depression.   ELE-101 is an intravenous formulation of psilocin designed to provide consistent and controllable drug delivery. As the active metabolite of psilocybin, psilocin has the potential to offer a rapid onset, significantly shorter treatment duration and reduced variability between patients, compared to oral formulations of psilocybin. This could enhance convenience and therapeutic outcomes for patients with depression while reducing the resource burden on healthcare systems   Today’s news release shares initial results from the Phase 1 part of the study and announces that the first patients have been dosed in the Phase 2a part.   Full press release here: https://lnkd.in/e4UfBhgg

This week, our Co-Founder and Co-CEO Florian Brand will be a keynote speaker at HLTH Europe in Amsterdam. Alongside Compass Pathways CEO Kabir Nath and Genevieve Wolff Jurvetson, Co-Founder of The Jurvetson Foundation they will discuss the current state of research in psychedelics for mental health, covering topics such as: 👉 How evidence-based psychedelic treatments could transform mental health care 👉 Insights from the latest clinical trials 👉 Delivery of care and patient access   Join the session on the main stage on Wednesday June 19 at 3pm CEST. Full agenda here: https://lnkd.in/dPU55jE8 #MentalHealth #PsychedelicTreatments #HLTHEurope

We have launched a new Impact Report and Peer Support Pilot Program in collaboration with the Psychedelic Participant Advocacy Network - PsyPAN. The report shares novel insights from psychedelic clinical trial participants and maps their experiences throughout a clinical trial, from recruitment and pre-treatment, to dosing and integration. The report aims to amplify the voice of the participant and highlights potential improvements for future participant experiences. In particular, the report spotlights the need for post-trial support. In light of this finding, we are proud to announce that we have given PsyPAN an unrestricted grant to initiate a 12-month peer support pilot program aimed at supporting trial participants in the UK. Caroline Lilley, Chief Impact Advisor at Beckley Psytech, said: “The launch of this report and PsyPAN’s peer support program is the culmination of an extensive, years-long collaboration between Beckley Psytech and PsyPAN. At Beckley Psytech, we are committed to listening to, and learning from, patient and participant experiences and I want to take this opportunity to thank the patient experts for their honesty and courage. We encourage all interested stakeholders to read the report and we hope to see further partnership between industry and patient groups in the future.” In recognition of the Patient Council project, and the collaboration between Beckley Psytech and PsyPAN, Beckley Psytech also announced today that it had received the Silver Standard in OVID Health's 2024 #PatientPartnershipIndex. The Index is an annual celebration of high-quality, meaningful partnerships between patient groups and pharmaceutical companies, and this is the second consecutive year that Beckley Psytech has been recognised for its patient-focused work. To read the report and learn more about the peer support program, please click here: https://lnkd.in/eYMam-AW

An estimated 3 million people in the US suffer from Opioid Use Disorder (OUD).   OUD and addiction, in general, are notoriously difficult to treat, with most current treatments inadequately addressing patients’ symptoms, and often leading to relapse.   At atai, we are committed to pioneering new treatment options for those suffering from the most challenging mental health conditions. We’re conducting a clinical program with ibogaine, IBX-210, for the treatment of OUD. Ibogaine has shown promising potential in reducing opioid cravings and supporting withdrawal symptoms in previous clinical studies. You can follow the progress of this program and our other clinical programs by visiting our website and signing up for email updates. https://atai.life/   Special thanks to Heather McKenzie at BioSpace for raising this important topic and covering our research. Read more: https://lnkd.in/eVMb-e7i   #Ibogaine #OpioidCrisis #AddictionTreatment #MentalHealth 

Last week our Co-CEO Dr Srinivas Rao, participated in a fireside chat with Andrew Tsai at the #JefferiesHealthcare conference. Among other topics they discussed the points raised at last week’s FDA AdCom and the learnings for psychedelics biotech companies moving forward.   Watch the replay of the discussion here: https://lnkd.in/e7TfTeTG

Our Co-CEO Srinivas Rao will be doing a fireside chat with Andrew Tsai today at the #JefferiesHealthcare Conference in New York at 10am ET. You can listen live by signing up for the webcast here - it will also be available for replay: https://lnkd.in/eq-GsVJN Srinivas will discuss atai’s upcoming milestones and share his thoughts on Tuesday's unprecedented FDA AdCom on MDMA-assisted therapy for PTSD.

Exciting new study from our friends at Beckley Psytech and The Centre for Psychedelic Research at Imperial College London. It is the first study of its kind to assess the effects of BPL-003, intranasal 5-MeO-DMT, in the human brain and may reveal novel insights into the mechanism of action of this compound.     Meanwhile, the Phase 2b study of BPL-003 in patients with treatment-resistant depression is currently underway with results expected in the second half of this year.     #PsychedelicResearch #MentalHealthInnovation #Neuroscience 

Next week our management team will be at the Jefferies Global Healthcare conference in New York. Co-CEO Srinivas Rao will participate in a fireside chat on Thursday June 6, at 10:00 a.m. ET. The discussion will be webcast live via the following link and the replay will be availlable on the Investors section of our website under Events. https://lnkd.in/eufKRfEC #JefferiesHealthcare #MentalHealth